SPS
NMRA icon

Susquehanna Portfolio Strategies’s Neumora Therapeutics NMRA Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313K Buy
160,319
+88,213
+122% +$229K ﹤0.01% 837
2025
Q4 		$129K Buy
72,106
+30,866
+75% +$67.6K ﹤0.01% 973
2025
Q3 		$75.1K Buy
+41,240
New +$66.7K ﹤0.01% 1014

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Susquehanna Portfolio Strategies's NMRA Position: Q1 2026 in Review

Susquehanna Portfolio Strategies increased its Neumora Therapeutics (NMRA) stake by 122% in Q1 2026, buying an estimated $229K and bringing the position to 160,319 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

Susquehanna Portfolio Strategies first reported a position in NMRA in Q3 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Susquehanna Portfolio Strategies held 160,319 shares of Neumora Therapeutics worth $313K as of Q1 2026.
  • Susquehanna Portfolio Strategies bought 88,213 Neumora Therapeutics shares in Q1 2026, an estimated $229K.
  • Neumora Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #837 holding.
  • Susquehanna Portfolio Strategies first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.